These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 29621988)

  • 1. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
    Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
    BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
    Mulyadi R; Hasan I; Sidipratomo P; Putri PP
    J Egypt Natl Canc Inst; 2024 May; 36(1):18. PubMed ID: 38797810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
    Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
    Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    J Comp Eff Res; 2018 Mar; 7(3):209-221. PubMed ID: 29231047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
    Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Kariya S; Yoshii K; Sekimoto M
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1217-1224. PubMed ID: 33906315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.